Analyst Insight: Recently, Big Pharma went through a significant period of mergers and acquisitions to gain a global market presence and product offering expansion. Now it appears the tides may be shifting. A segment of Big Pharma is shedding non-core business units and focusing on core profitability. But the acquisition strategy is not dead. These diverging paths are both focused on increasing flexibility and profitability to adapt to market uncertainty. Supply chain planning and adaptability have moved forward as integration of business units has increased in all regions of the globe. - Brian Hudock, partner, Tompkins International